Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease

Gil D Rabinovici^{1

2}, Renaud La Joie¹

Affiliations

¹ Memory & Aging Center, Department of Neurology, University of California San Francisco.
² Department of Radiology & Biomedical Imaging, University of California San Francisco.

Editorial

Gil D Rabinovici et al. JAMA. 2023.

. 2023 Aug 8;330(6):507-509.

doi: 10.1001/jama.2023.11703.

Gil D Rabinovici^{1

2}, Renaud La Joie¹

¹ Memory & Aging Center, Department of Neurology, University of California San Francisco.
² Department of Radiology & Biomedical Imaging, University of California San Francisco.

No abstract available

Comment in

Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
Manly JJ, Deters KD. Manly JJ, et al. JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704. JAMA. 2023. PMID: 37459138 No abstract available.

Ushering in a New Era of Alzheimer Disease Therapy.
Widera EW, Brangman SA, Chin NA. Widera EW, et al. JAMA. 2023 Aug 8;330(6):503-504. doi: 10.1001/jama.2023.11701. JAMA. 2023. PMID: 37459123 No abstract available.
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
Rosenthal MB. Rosenthal MB. JAMA. 2023 Aug 8;330(6):505-506. doi: 10.1001/jama.2023.11702. JAMA. 2023. PMID: 37459140 No abstract available.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.